Moderna stock surged approximately 9% on Friday, reaching a price of $149, driven primarily by a significant Phase 3 clinical trial win for its personalized mRNA cancer vaccine in partnership with Merck. The trial demonstrated that the vaccine, known as intismeran autogene (mRNA-4157), significantly reduced...
Moderna (NASDAQ: MRNA) shares surged approximately 90% in pre-market trading on Wednesday following the announcement of positive Phase 3 clinical trial results for its personalized mRNA-based cancer vaccine, intismeran (mRNA-4157), developed in partnership with Merck. The stock, which had closed the previous session at roughly...
Moderna (MRNA) experienced extreme stock volatility following the release of Phase 3 trial data for its mRNA cancer vaccine candidate, intismeran autogene (mRNA-4157). The stock surged 177% on Wednesday after the combination therapy met key goals in a study of patients with advanced melanoma, showing...
Moderna Inc. (NASDAQ: MRNA) shares surged approximately 6.21% on Tuesday, June 23, 2026, driven by a unanimous FDA advisory committee vote favoring its mRNA-1010/mFLUSIVA seasonal flu vaccine for adults aged 50 and older. The stock climbed from roughly $47 to $63 over the preceding month,...
Moderna (MRNA) stock has surged for a fifth consecutive day following the publication of FDA briefing documents indicating that immunogenicity data from its mFlusiva flu shot may support effectiveness in adults aged 65 and older. This represents a significant regulatory shift, as the FDA had...
Moderna (MRNA) shares surged 17.4% in the afternoon session after the company settled a long-running patent dispute with Arbutus Biopharma and Genevant Sciences. The agreement, valued at up to $2.25 billion, resolves legal uncertainties surrounding the technology used in its COVID-19 vaccine and eliminates future...
Moderna Inc. reported strong second-quarter 2026 financial results, generating revenue of USD 145.00 million against a consensus estimate of USD 102.93 million, representing a significant beat. The company also posted earnings per share (EPS) of USD -1.97, which exceeded the estimated loss of USD -2.03...
Moderna Inc (MRNA) reported Q1 2026 revenue of $400 million, representing a significant $300 million year-over-year increase, with costs of sales rising to $955 million primarily due to an $878 million litigation settlement related to Arbutus and Genevant. On a GAAP basis, the company recorded...
Moderna Inc. (MRNA) shares surged 12.27 percent to close at USD 172.94 on September 21, 2026, significantly outperforming the Nasdaq Composite's 2.26 percent gain. The stock traded in a range between USD 154.04 and USD 176.86, reaching a new 52-week high with trading volume of...
Moderna Inc. shares rose to $158.07 on September 17, 2026, driven by positive Phase 3 clinical data for its personalized mRNA cancer vaccine and a wave of fresh analyst upgrades. The company's stock gained over 100% in the past month as investors re-evaluate oncology as...
Moderna (MRNA) shares surged 14% to $68 in Friday afternoon trading, reaching a new 52-week high of $69.29. The rally significantly outpaced peers Merck (MRK), which rose 2%, and Pfizer (PFE), which gained 2%. Analysts attribute the move to momentum from a recent FDA advisory...
Moderna (MRNA) shares surged 9% today, extending a remarkable 94% gain year-to-date to trade near $57. This performance significantly outpaces peers Pfizer (PFE), which is up 4%, and Novavax (NVAX), which is up 41%. The rally is driven by corporate restructuring rather than new clinical...
The article argues that while Moderna (MRNA) recently surged 63% year-to-date following a Q1 revenue triple, its long-term fundamentals remain weak. Full-year 2025 revenue collapsed to $1.94 billion, a roughly 40% drop, with management projecting only up to 10% growth for 2026 off this depressed...
Moderna (NASDAQ:MRNA) was ranked number one on TIME's 2026 list of the World's Most Impactful Companies, a distinction based on the Upright Project's Net Impact Model which evaluates net-positive contributions across Society, Knowledge, Health, and Environment. The recognition highlights Moderna's status as a pioneer in...
Moderna (MRNA) shares surged 16% on March 4 after the company reached a settlement with Arbutus Biopharma and Genevant Sciences regarding patents for its COVID vaccines. The agreement includes a one-time payment of $950 million to Moderna, with no future royalties required. This resolution removes...
Moderna Inc. stock closed at USD 154.03 on the Nasdaq on September 18, 2026, marking a strong rally driven by positive Phase 3 clinical data for a personalized cancer vaccine. This progress has shifted investor perception away from the pandemic-vaccine narrative, repositioning the company as...
Moderna (MRNA) shares surged approximately 6% to $154 in morning trading on Thursday, extending a remarkable 137% gain over the past month. This rally occurred without any new trial results or analyst upgrades, driven primarily by the market's continued digestion of late-stage adjuvant melanoma data...
Moderna (MRNA) shares have retreated significantly following a sharp surge driven by positive late-stage trial results for its experimental melanoma cancer vaccine developed in partnership with Merck. While the company recently reported good data, Rothschild & Co Redburn argues that the stock is now 'considerably...
Moderna (MRNA) shares fell 18% to $142.70 on Thursday, reversing a historic 177% rally from Wednesday following the announcement of a Phase 3 win for its personalized cancer vaccine, intismeran. The trial demonstrated a meaningful reduction in melanoma recurrence when paired with Merck's Keytruda, validating...
Brookline Capital Markets analyst L. Cann raised its Q2 2026 earnings per share (EPS) estimate for Moderna to ($1.97), a slight improvement from the previous forecast of ($1.98). The firm also provided forward guidance, projecting Q3 EPS at ($1.30), Q4 at ($2.16), full-year 2026 EPS...
